A Meta-analysis on Shensong Yangxin Capsules for treating early recurrence of atrial fibrillation after radiofrequency ablation
Li Hengda
Bao Yu
Hu Yucai
Zhao Zhiqiang
Abstract：Objective To review systematically the effectiveness and safety of Shensong Yangxin Capsules in treatment of early recurrence of atrial fibrillation(ERAF)after radiofrequency ablation(RFA).Methods The databases of CNKI,WanFang,VIP,SinoMed,PubMed,Web of Science and Cochrane Library were retrieved for collecting RCT of Shensong Yangxin Capsules in treatment of ERAF after RFA from the inception of the databases until 2023.The literatures were screened according to inclusion and exclusion criteria,given a Meta-analysis by using RevMan 5.3 software,and outcome indicators were reviewed by using GRADE evidence rating evaluation system.Results There were totally 9 RCT included with 1315 patients,and there were 657 in test group and 658 in control group.The results of Meta-analysis showed that Shensong Yangxin Capsules decreased AF recurrence rate(RR=0.54,95％CI:0.42～0.69,P＜0.00001),left atrial diameter(LAD,MD=-1.93,95％CI:-2.90～-0.96,P＜0.0001),left ventricular end-diastolic diameter(LVEDD,MD=-3.38,95％CI:-3.93～-2.83,P＜0.00001),left ventricular end-systolic diameter(LVESD,MD=-1.81,95％CI:-2.28～-1.34,P＜0.00001),and N-terminal pro-brain natriuretic peptide(NT-proBNP,MD=-88.07,95％CI:-122.77～-53.36,P＜0.00001).Shensong Yangxin Capsules increased the total clinical efficacy(RR=1.17,95％CI:1.02～1.34,P=0.02),left ventricular ejection fraction(LVEF,MD=2.43,95％CI:1.95～2.90,P＜0.00001),ratio of early diastolic mitral valve flow velocity to late diastolic mitral valve flow velocity(E/A,MD=0.24,95％CI:0.13～0.35,P＜0.0001),and scores of Atrial Fibrillation Effect on Quality-of-Life(AFEQT,MD=9.34,95％CI:4.70～13.98,P＜0.0001).Shensong Yangxin Capsules had higher safety(RD=0.01,95％CI:-0.01～0.03,P=0.51).Conclusion Shensong Yangxin Capsules is superior to conventional Western medicine therapy in reducing ERAF after RFA with higher safety.Due to the limitations of quantity and quality of included studies,the above conclusions still need to be validated by more RCT with larger sample,multicenter and high quality.
Keywords：Atrial fibrillationShensong Yangxin CapsulesRadiofrequency ablationMeta-analysis
Publication Date：2024-08-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：8( 924-931 )